PRMT5 and lymphoma: Inhibition of PRMT5 showed decreased cell viability in preclinical testing and as a result, several PRMT5 inhibitors (GSK3326595, AMG193, JNJ64619178/Onametostat, PF06939999, TNG908, PRT811, PRT543, and MRTX1719) have been developed and are in early phase clinical development for metastatic solid tumors and lymphoma demonstrating MTAP deletion.